A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer
Latest Information Update: 21 Apr 2023
Price :
$35 *
At a glance
- Drugs Ispinesib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Jul 2007 Status change from in progress to completed
- 27 Jul 2007 The expected completion date for this trial is now .
- 01 Oct 2005 New trial record.